ATE214920T1 - Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen veränderungen - Google Patents

Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen veränderungen

Info

Publication number
ATE214920T1
ATE214920T1 AT99308129T AT99308129T ATE214920T1 AT E214920 T1 ATE214920 T1 AT E214920T1 AT 99308129 T AT99308129 T AT 99308129T AT 99308129 T AT99308129 T AT 99308129T AT E214920 T1 ATE214920 T1 AT E214920T1
Authority
AT
Austria
Prior art keywords
compound
activity
determining
pde
cox
Prior art date
Application number
AT99308129T
Other languages
English (en)
Inventor
Li Liu
Bing Zhu
Li Han
Joseph W Thompson
Rifat Pamukeu
Gary A Piazza
Original Assignee
Cell Pathways Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/173,375 external-priority patent/US6200771B1/en
Priority claimed from US09/366,003 external-priority patent/US6130053A/en
Priority claimed from US09/414,628 external-priority patent/US20020009764A1/en
Application filed by Cell Pathways Inc filed Critical Cell Pathways Inc
Application granted granted Critical
Publication of ATE214920T1 publication Critical patent/ATE214920T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99308129T 1998-10-15 1999-10-14 Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen veränderungen ATE214920T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/173,375 US6200771B1 (en) 1998-10-15 1998-10-15 Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US09/366,003 US6130053A (en) 1999-08-03 1999-08-03 Method for selecting compounds for inhibition of neoplastic lesions
US09/414,628 US20020009764A1 (en) 1999-10-08 1999-10-08 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds

Publications (1)

Publication Number Publication Date
ATE214920T1 true ATE214920T1 (de) 2002-04-15

Family

ID=27390268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99308129T ATE214920T1 (de) 1998-10-15 1999-10-14 Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen veränderungen

Country Status (13)

Country Link
EP (2) EP0997145B1 (de)
JP (1) JP2000186047A (de)
CN (1) CN100389829C (de)
AT (1) ATE214920T1 (de)
AU (1) AU770308B2 (de)
CA (1) CA2284853A1 (de)
DE (1) DE69901082T2 (de)
DK (1) DK0997145T3 (de)
ES (1) ES2174573T3 (de)
IL (1) IL132366A0 (de)
NO (2) NO994995L (de)
TR (1) TR199902578A2 (de)
TW (1) TWI239837B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1833000A (en) * 1998-11-25 2000-06-19 Cell Pathways, Inc. Method for diagnosing neoplasia
US6569638B1 (en) * 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
AU2001278609B2 (en) * 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
WO2004044234A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
US9408405B2 (en) 2003-10-03 2016-08-09 Veijlen N.V. Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
US7659426B2 (en) 2003-12-01 2010-02-09 Reverse Proteomics Research Institute Co., Ltd. Target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
JP5219135B2 (ja) * 2008-07-25 2013-06-26 独立行政法人産業技術総合研究所 炎症性疾患モデル動物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508586B1 (de) * 1991-03-08 1995-05-31 Fgn, Inc. Substituierte Indenylverbindungen
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US5998477A (en) * 1996-06-13 1999-12-07 Cell Pathways Inc. Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
CA2266496A1 (en) * 1996-09-18 1998-03-26 Codon Pharmaceuticals, Inc. Pharmaceutical compositions and methods
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia

Also Published As

Publication number Publication date
EP0997145A1 (de) 2000-05-03
NO20062682L (no) 2000-04-17
CA2284853A1 (en) 2000-04-15
NO994995L (no) 2000-04-17
ES2174573T3 (es) 2002-11-01
AU770308B2 (en) 2004-02-19
TR199902578A3 (tr) 2000-06-21
NO994995D0 (no) 1999-10-14
EP1161943A2 (de) 2001-12-12
TR199902578A2 (xx) 2000-06-21
AU5401099A (en) 2000-04-20
DE69901082D1 (de) 2002-05-02
IL132366A0 (en) 2001-03-19
CN1255379A (zh) 2000-06-07
TWI239837B (en) 2005-09-21
CN100389829C (zh) 2008-05-28
EP0997145B1 (de) 2002-03-27
DK0997145T3 (da) 2002-07-29
EP1161943A3 (de) 2003-12-10
DE69901082T2 (de) 2002-08-29
JP2000186047A (ja) 2000-07-04

Similar Documents

Publication Publication Date Title
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
EP1379251A4 (de) Hemmstoffe der akt aktivität
DK0770065T3 (da) Trisubstituerede phenylderivater nyttige som PDE IV-inhibitorer
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
WO2003103653A8 (en) Methods of treating alzheimer's disease using aryl alkanoic acid amides
DE69805672D1 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
ATE198771T1 (de) Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen verletzungen
ATE202354T1 (de) Tetracyclische kondensierte heterocyclische verbindungen zur behandlung von seniler demenz
DE69901082D1 (de) Verfahren zur Identifizierung von Verbindungen zur Hemmung von neoplastischen Veränderungen
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
BR9508342A (pt) Compostos orgânicos
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE69330465D1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
DE60121225D1 (de) Tetrapeptidische tryptase substrate und ihre verwendung zur tryptase aktivitätbestimmung
NZ512546A (en) Use of actylcholine esterase inhibitors to treat delirium
FR2788707B1 (fr) Procede de traitement d'un substrat par des particules photocatalytiques
DE60210769D1 (de) Verwendung von bicyklischen verbindungen für die behandlung von alzheimer
DE60312656D1 (de) Arzneimittel zur behandlung von störungen des zirkadianen rhythmus
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
ATE92077T1 (de) Enzymhemmer und methode zu dessen herstellung.
ATE360432T1 (de) Peptid zur behandlung von nervenerkrankungen
ECSP982536A (es) Compuestos utiles para la inhibicion de transferasa de proteina al farnesilo ( case ino750k)
AR248382A1 (es) Metodo para inhibir el crecimiento de por lo menos un microorganismo en un sistema industrial susceptible al crecimiento de un microorganismo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee